TORONTO--(BUSINESS WIRE)--May 3, 2005-- MIRA-1 Trial Progress Also Updated OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) announced that Reinhard Klingel, M.D., Ph.D. of the Apheresis Research Institute, Cologne, Germany, today presented updated Rheopheresis(TM) (“RHEO”) safety and efficacy data from the reference controlled RheoNet Registry and reported on MIRA-1 study progress at the Association for Research in Vision and Ophthalmology (“ARVO”) Annual Meeting in Fort Lauderdale, Florida.
